Enanta Pharmaceuticals Inc (ENTA): EBITDA
-$80.76M
Year ended 2025-09-30
-$53.82M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-09-30 | -$80.76M | n/m | 2025-11-19, From 2024-10-01 |
| 2024-09-30 | -$119.36M | n/m | 2025-11-19, From 2023-10-01 |
| 2023-09-30 | -$134.84M | n/m | 2025-11-19, From 2022-10-01 |
| 2022-09-30 | -$120.87M | n/m | 2024-11-27, From 2021-10-01 |
| 2021-09-30 | -$106.24M | n/m | 2023-11-22, From 2020-10-01 |
| 2020-09-30 | -$37.99M | n/m | 2022-11-23, From 2019-10-01 |
| 2019-09-30 | $40.00M | -56.0% | 2021-11-24, From 2018-10-01 |
| 2018-09-30 | $90.85M | +239.6% | 2020-11-25, From 2017-10-01 |
| 2017-09-30 | $26.75M | -17.7% | 2019-11-27, From 2016-10-01 |
| 2016-09-30 | $32.50M | -74.0% | 2018-11-29, From 2015-10-01 |
| 2015-09-30 | $124.79M | +545.3% | 2017-12-11, From 2014-10-01 |
| 2014-09-30 | $19.34M | +109.0% | 2016-12-09, From 2013-10-01 |
| 2013-09-30 | $9.25M | -56.9% | 2015-12-11, From 2012-10-01 |
| 2012-09-30 | $21.46M | -16.8% | 2014-12-11, From 2011-10-01 |
| 2011-09-30 | $25.80M | n/a | 2013-12-18, From 2010-10-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | -$80.76M | n/m |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $6.31M | n/m |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | -$211.32M | n/m |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | -$2.50M | n/m |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | -$362.94M | n/m |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | -$11.99M | n/m |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | -$240.64M | n/m |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | -$4.38M | n/m |
| Nektar Therapeutics (NKTR) | 2025-12-31 | -$139.08M | n/m |
Compare ENTA, SPRO, NUVB, RMTI side by side · Screen every company in Pharmaceutical Preparations ↗